Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dublin, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The "Negotiation Skills for Contracts and Commercial Managers Training Course (Mar 16, 2026)" training has been added to ResearchAndMarkets.com's offering....
-
Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming...
-
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli...
-
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Hub Group To Contact Him Directly To Discuss Their Options If you...
-
Dublin, Feb. 05, 2026 (GLOBE NEWSWIRE) -- The "Frost Radar: Workforce Engagement Management, 2025" report has been added to ResearchAndMarkets.com's offering.A Benchmarking System to Spark...
-
Dublin, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The "Understanding and Managing Contracts to Achieve Better Results Training Course (April 15-16, 2026)" training has been added to ...
-
Austin, TX, USA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Life Insurance Policy Administration Systems Market Size, Trends and Insights By...
-
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
-
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
-
Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Building and Managing a Patent Portfolio to Best Support your Business Training Course (May 11, 2026)" has been added to ResearchAndMarkets.com's...